^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tagrisso (osimertinib)

    i
    Company:
    AstraZeneca
    Drug class:
    EGFR inhibitor
    Related drugs:
    Apply
    Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer (NCT04181060)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    12/28/2020
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib) • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Krabeva (bevacizumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change (NCT03191149)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    04/25/2018
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    EGFR • PD-1 • CTLA4
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib)
    Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib (Acclaim-1) (NCT04486833)
    Phase 1/2
    Genprex, Inc.
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    09/03/2021
    Primary completion :
    03/01/2028
    Completion :
    03/01/2029
    EGFR
    |
    EGFR mutation
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • Reqorsa (quaratusugene ozeplasmid)
    A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) (NCT03940703)
    Phase 2
    EMD Serono Research & Development Institute, Inc.
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    09/19/2019
    Primary completion :
    05/11/2023
    Completion :
    10/31/2025
    EGFR • MET
    |
    EGFR mutation • MET amplification
    |
    Tagrisso (osimertinib) • Tepmetko (tepotinib)
    Osimertinib Alone or with Chemotherapy for EGFR-Mutant Lung Cancers (NCT04410796)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    05/28/2020
    Primary completion :
    05/01/2025
    Completion :
    05/01/2025
    EGFR
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • carboplatin • pemetrexed
    Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study (ROSE) (NCT05089916)
    Phase 2
    AIO-Studien-gGmbH
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    01/20/2022
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    EGFR
    |
    EGFR mutation • EGFR T790M • EGFR positive
    |
    Tagrisso (osimertinib)
    A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA) (NCT04487080)
    Phase 3
    Janssen Research & Development, LLC
    Active, not recruiting
    Last update posted :
    02/12/2025
    Initiation :
    09/30/2020
    Primary completion :
    08/11/2023
    Completion :
    06/29/2027
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)
    A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (SKB264-II-04) (NCT05816252)
    Phase 2
    Klus Pharma Inc.
    Recruiting
    Last update posted :
    02/12/2025
    Initiation :
    04/19/2023
    Primary completion :
    12/01/2025
    Completion :
    10/30/2026
    EGFR • ALK
    |
    EGFR mutation • ALK fusion
    |
    Keytruda (pembrolizumab) • Tagrisso (osimertinib) • carboplatin • Jiataile (sacituzumab tirumotecan)
    A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (CHRYSALIS-2) (NCT04077463)
    Phase 1
    Janssen Research & Development, LLC
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    09/04/2019
    Primary completion :
    02/03/2025
    Completion :
    06/03/2026
    EGFR • MET
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR expression • MET expression • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)
    A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PALOMA-2) (NCT05498428)
    Phase 2
    Janssen Research & Development, LLC
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    11/11/2022
    Primary completion :
    10/31/2025
    Completion :
    08/05/2026
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib) • amivantamab SC (Ami-LC)
    OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain (NCT06068049)
    Phase N/A
    AstraZeneca
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    07/28/2023
    Primary completion :
    06/15/2029
    Completion :
    06/15/2029
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib)
    Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib (SAVANNAH) (NCT03778229)
    Phase 2
    AstraZeneca
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    01/09/2019
    Primary completion :
    08/23/2024
    Completion :
    05/28/2025
    EGFR • MET
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR amplification • MET overexpression
    |
    Tagrisso (osimertinib) • Orpathys (savolitinib)
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCI-MATCH) (NCT02465060)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/17/2015
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    MSI • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bicalutamide • leucovorin calcium • bendamustine • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • GSK2636771 • Zirabev (bevacizumab-bvzr) • defactinib (VS-6063) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Provenge (sipuleucel-T) • TQB2440 (pertuzumab biosimilar) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • BCD-178 (pertuzumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)
    Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer (NCT03810807)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    01/17/2019
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    EGFR
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • Vizimpro (dacomitinib)
    Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation (ORBITAL) (NCT04233021)
    Phase 2
    Intergroupe Francophone de Cancerologie Thoracique
    Completed
    Last update posted :
    02/03/2025
    Initiation :
    07/16/2020
    Primary completion :
    03/15/2023
    Completion :
    12/27/2024
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X
    |
    Tagrisso (osimertinib)
    A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC (CoC) (NCT04606771)
    Phase 2
    AstraZeneca
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    09/28/2020
    Primary completion :
    12/21/2022
    Completion :
    03/28/2025
    MET
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification
    |
    Tagrisso (osimertinib) • Orpathys (savolitinib)
    Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery (NCT03433469)
    Phase 2
    University of California, San Francisco
    Active, not recruiting
    Last update posted :
    01/31/2025
    Initiation :
    07/31/2018
    Primary completion :
    01/31/2023
    Completion :
    10/31/2026
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    Tagrisso (osimertinib)
    Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M (AZENT) (NCT02841579)
    Phase 2
    MedSIR
    Completed
    Last update posted :
    01/28/2025
    Initiation :
    09/02/2016
    Primary completion :
    12/01/2018
    Completion :
    02/14/2020
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR L861Q • EGFR G719X
    |
    Tagrisso (osimertinib)
    Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC (STU 122017-017) (NCT03667820)
    Phase 2
    University of Texas Southwestern Medical Center
    Active, not recruiting
    Last update posted :
    12/27/2024
    Initiation :
    09/26/2018
    Primary completion :
    03/30/2025
    Completion :
    04/01/2025
    EGFR
    |
    EGFR mutation
    |
    Tagrisso (osimertinib)
    Osimertinib In EGFR Mutant Lung Cancer (NCT03586453)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    11/19/2024
    Initiation :
    08/13/2018
    Primary completion :
    02/28/2026
    Completion :
    03/01/2027
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib)
    18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma (NCI-2018-02010) (NCT03732352)
    Phase 2
    Jonsson Comprehensive Cancer Center
    Completed
    Last update posted :
    11/12/2024
    Initiation :
    11/28/2018
    Primary completion :
    01/31/2024
    Completion :
    01/31/2024
    EGFR • TP53
    |
    TP53 mutation • EGFR mutation • EGFR amplification
    |
    Tagrisso (osimertinib)
    Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC (NCT03769103)
    Phase 2
    British Columbia Cancer Agency
    Active, not recruiting
    Last update posted :
    10/31/2024
    Initiation :
    03/19/2019
    Primary completion :
    04/01/2025
    Completion :
    04/01/2025
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib)
    Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge (OCELOT) (NCT04335292)
    Phase 2
    Mark Vincent
    Recruiting
    Last update posted :
    10/22/2024
    Initiation :
    01/06/2021
    Primary completion :
    06/01/2026
    Completion :
    06/01/2027
    EGFR
    |
    EGFR mutation
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed
    Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer (NCT03122717)
    Phase 1/2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    09/26/2024
    Initiation :
    05/09/2017
    Primary completion :
    04/01/2025
    Completion :
    04/01/2026
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • gefitinib
    A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NCT05880706)
    Phase 2
    Sichuan Baili Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    08/07/2024
    Initiation :
    07/19/2023
    Primary completion :
    07/01/2025
    Completion :
    07/01/2025
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • izalontamab brengitecan (BL-B01D1)
    A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) (TARGET) (NCT05526755)
    Phase 2
    AstraZeneca
    Recruiting
    Last update posted :
    06/14/2024
    Initiation :
    03/06/2023
    Primary completion :
    04/05/2029
    Completion :
    04/05/2029
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Tagrisso (osimertinib)
    Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer (UCLA l-08) (NCT04285671)
    Phase 1/2
    Jonsson Comprehensive Cancer Center
    Active, not recruiting
    Last update posted :
    06/13/2024
    Initiation :
    01/29/2021
    Primary completion :
    12/02/2025
    Completion :
    12/02/2026
    HER-2 • AXL
    |
    EGFR mutation • EGFR L858R • HER-2 expression • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib) • Herzuma (trastuzumab-pkrb) • Trazimera (trastuzumab-qyyp) • Portrazza (necitumumab)
    Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) (Lung-MAP Sub-Study) (NCT05642572)
    Phase 2
    SWOG Cancer Research Network
    Recruiting
    Last update posted :
    06/11/2024
    Initiation :
    05/05/2023
    Primary completion :
    05/31/2026
    Completion :
    05/31/2027
    EGFR • MET
    |
    EGFR mutation • MET amplification
    |
    Tagrisso (osimertinib) • Cyramza (ramucirumab) • Tabrecta (capmatinib)
    Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer (NCI-2019-05913) (NCT04085315)
    Phase 1
    Collin Blakely
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    11/12/2019
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR E709K • EGFR exon 19 insertion • EGFR H835L • EGFR L833V • EGFR V834L
    |
    Tagrisso (osimertinib) • alisertib (MLN8237)
    A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection (ADAURA2) (NCT05120349)
    Phase 3
    AstraZeneca
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    02/21/2022
    Primary completion :
    08/02/2027
    Completion :
    11/01/2032
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib)
    Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib (NCT02759835)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    06/07/2024
    Initiation :
    04/13/2016
    Primary completion :
    05/25/2022
    Completion :
    09/20/2022
    EGFR
    |
    EGFR mutation • EGFR T790M
    |
    Tagrisso (osimertinib)
    Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study (NCT03381274)
    Phase 1/2
    MedImmune LLC
    Active, not recruiting
    Last update posted :
    06/06/2024
    Initiation :
    05/08/2018
    Primary completion :
    05/24/2021
    Completion :
    07/15/2025
    EGFR
    |
    EGFR T790M negative
    |
    Tagrisso (osimertinib) • oleclumab (MEDI9447) • imaradenant (AZD4635)
    Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer (NCT04479306)
    Phase 1
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    06/04/2024
    Initiation :
    06/18/2020
    Primary completion :
    07/27/2023
    Completion :
    07/27/2023
    EGFR • PD-L1
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L858R + EGFR exon 21 deletion
    |
    Tagrisso (osimertinib) • sapanisertib (CB-228) • alisertib (MLN8237)
    Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor (NCT02496663)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/04/2024
    Initiation :
    05/11/2016
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR exon 20 mutation • EGFR T790M negative
    |
    Tagrisso (osimertinib) • Portrazza (necitumumab)
    Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation (PIKACHU) (NCT04322890)
    Phase 2
    Hunan Province Tumor Hospital
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    04/16/2020
    Primary completion :
    12/24/2026
    Completion :
    12/24/2027
    EGFR • BRAF • ALK • ROS1
    |
    EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation
    |
    cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • erlotinib • gefitinib • Rozlytrek (entrectinib) • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Ameile (aumolertinib) • Orpathys (savolitinib) • Ivesa (firmonertinib)
    Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment (SAFFRON) (NCT05261399)
    Phase 3
    AstraZeneca
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    08/03/2022
    Primary completion :
    06/26/2025
    Completion :
    12/17/2026
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR overexpression • MET overexpression • MET mutation
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Orpathys (savolitinib)
    The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC (NCT06109558)
    Phase 1/2
    Hunan Province Tumor Hospital
    Recruiting
    Last update posted :
    05/30/2024
    Initiation :
    12/31/2023
    Primary completion :
    12/30/2026
    Completion :
    07/30/2027
    EGFR • MET • RET
    |
    MET amplification • RET fusion • EGFR T790M negative
    |
    Tagrisso (osimertinib)
    Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC (NCT06436144)
    Phase 2
    Daping Hospital and the Research Institute of S...
    Not yet recruiting
    Last update posted :
    05/30/2024
    Initiation :
    06/01/2024
    Primary completion :
    06/01/2029
    Completion :
    12/01/2029
    EGFR
    |
    Tagrisso (osimertinib) • etoposide oral
    Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm (NCT05546866)
    Phase 2
    AstraZeneca
    Recruiting
    Last update posted :
    05/29/2024
    Initiation :
    02/21/2023
    Primary completion :
    06/30/2029
    Completion :
    06/30/2029
    EGFR
    |
    EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib)
    Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer (NCT05954871)
    Phase 1
    Genentech, Inc.
    Recruiting
    Last update posted :
    05/29/2024
    Initiation :
    01/08/2024
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    KRAS • BRAF • NRAS
    |
    BRAF V600E • EGFR mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR positive
    |
    Erbitux (cetuximab) • Tagrisso (osimertinib) • migoprotafib (RLY-1971)